Validating MARK2 Gene Polymorphism as a Predictor of Response to Lithium Treatment in Bipolar Patients

BACKGROUND: Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However, it is estimated that 10 to 60% of patients do not properly response to this medication. METHODS: To investigate the role of MARK2 gene in respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghabozorg Afjeh, Sara Sadat, Shams, Jamal, Hamednia, Safar, Boshehri, Behzad, Amini, Asmaolhosna, Omrani, Amin, Omrani, Mir Davood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute of Iran 2022
Materias:
Full Length
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987413/
https://www.ncbi.nlm.nih.gov/pubmed/34953473
http://dx.doi.org/10.52547/ibj.26.2.110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987413/
https://www.ncbi.nlm.nih.gov/pubmed/34953473
http://dx.doi.org/10.52547/ibj.26.2.110

Ejemplares similares